B836 / Nanolattix - LARVOL DELTA

B836: A novel bispecific antibody-drug conjugate (ADC) as a clinical candidate to overcome trastuzumab deruxtecan resistance (AACR 2026) - "Resistance to single-antigen HER2-targeted ADCs, such as Enhertu (trastuzumab deruxtecan, DS-8201) and Kadcyla (trastuzumab emtansine, T-DM1), poses a significant challenge in HER2-positive cancers, often due to tumor heterogeneity and antigen downregulation. Furthermore, no systemic toxicity was detected at doses up to 5 mg/kg. These collective findings support the continued clinical development of B836, promising therapeutic potential in oncology."

ADC • Bispecific • Clinical • Oncology • HER-2